Page 1

Halozyme Exhibit 99.1 HALOZYME REPORTS THIRD QUARTER 2021 RESULTS - Record Quarterly Royalties in the Third Quarter of $ 58.6 million Representing 145 % Growth over Third Quarter 2020 _ - Third Quarter Revenue of $ 115.8 million with GAAP Diluted Earnings per Share of $ 1.48 and Non - GAAP Diluted Earnings per Share of $ 0.55 - -Increasing Lower End of Revenue and Operating Income 2021 Guidance Ranges to Reflect Strong Third Quarter Results - - Increasing GAAP Diluted Earnings per Share 2021 Guidance to Reflect an Income Tax Benefit Related to the Release of a Valuation Allowance for Deferred Tax Assets , Increasing Lower End of Non - GAAP Diluted Earnings per Share 2021 Guidance - SAN DIEGO , November 2 , 2021 - Halozyme Therapeutics , Inc. ( NASDAQ : HALO ) today reported financial results for the third quarter ended September 30 , 2021 and provided an update on its recent corporate activities and outlook . " Our strong 2021 performance continued in the third quarter fueled by 145 % growth over the prior year period in revenue from royalties . We continue to project that full year royalty revenue in 2021 will be more than double 2020 royalty revenue . Our topline growth in turn resulted in strong profitability for the quarter , " said Dr. Helen Torley , president and chief executive officer . " We look forward to additional study starts before year - end as our partners continue making progress in the clinic developing products utilizing our ENHANZE® technology , with the goal of providing patients with additional treatment options . " Recent Partner Highlights : • • In July 2021 , Janssen elected the target HIV reverse transcriptase , representing the third target selected by Janssen for development with ENHANZE® . In July 2021 , Janssen received U.S. Food and Drug Administration approval for DARZALEX FASPROⓇ in combination with pomalidomide and dexamethasone for patients with multiple myeloma after first or subsequent relapse . In October 2021 , Janssen's DARZALEX FASPROⓇ was approved by the China National Medical Products Administration ( NMPA ) for the treatment of primary light chain amyloidosis , in combination with bortezomib , cyclophosphamide and dexamethasone ( D - VCd ) in newly diagnosed patients . This followed a similar approval Janssen Pharmaceutical K.K. received in